Promising Lp(a)–Lowering Drug Falls Short in Major Heart Trials
TL;DR Summary
Three companies tested drugs that dramatically lower the blood protein Lp(a) to prevent heart attacks and strokes. Novartis revealed that although the therapy reduced Lp(a) by up to 80%, it did not reduce cardiovascular events, a surprising setback that raises questions about whether Lp(a) is a causal factor or just a marker, with results from other trials still awaited at the upcoming American Heart Association meeting.
- A Promising Heart Drug Failed. What Went So Wrong? The New York Times
- Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field STAT
- Cholesterol drug setback casts doubt over multibillion-dollar race CNBC
- One Stock Is Weighing Heavily on the Dow Barron's
- Doctors thought this heart breakthrough was coming. Then everything changed Cleveland.com
Reading Insights
Total Reads
1
Unique Readers
7
Time Saved
14 min
vs 15 min read
Condensed
98%
2,815 → 66 words
Want the full story? Read the original article
Read on The New York Times